An analysis of the phase 3 ARASENS study revealed new information on prostate-specific antigen (PSA) responses and their association with outcomes. The study, led by Fred Saad, MD, FRCS, and colleagues, analyzed the efficacy of darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). ...
mCSPC
Advertisement
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
A combination of androgen annihilation therapy with radiotherapy was tested for recurrent metastatic prostate cancer.
Investigators evaluated the data of 427 patients with metastatic HSPC and serum initial PSA greater than 100 ng/ml.
Dr. Aggarwal also discusses next steps regarding the intensification of ADT in patients with BRPC.
Phase III mHSPC trials can take up to a decade to complete when OS is used as the primary endpoint.
The addition of apalutamide to ADT should be considered in patients with high-risk BRPC, according to researchers.
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Researchers evaluated real-world survival for patients with mCSPC who received enzalutamide or apalutamide treatment.
Advertisement
Prostate Cancer Knowledge Hubs
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Latest News
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
